Bio-Techne Overview
Valuation check: TECH's P/S ratio is 10.37, above the Healthcare sector average of 6.4.
Get informed when a big investor buys or sells
+ Follow10.37
Price-to-Sales ratio compares a company's stock price to its revenue per share. A lower P/S ratio may indicate that the stock is undervalued relative to its sales.
The latest P/S ratio for TECH is 10.37. That is above the Healthcare sector average of 6.4. Investors often review this figure alongside Bio-Techne's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, TECH currently prints 10.37 for P/S ratio, while the sector average sits near 6.4. That is roughly 62.1% above the sector mean. Large gaps often invite a closer look at Bio-Techne's growth, margins, and balance sheet.
A P/S ratio of 10.37 for Bio-Techne is not 'good' or 'bad' on its own. Compare it with the peer average (6.4) and with TECH's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TECH's P/S ratio (10.37), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Bio-Techne's P/S ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
